Introduction
With improvements in patient and graft survival after transplantation in the last decade, increasing attention has been placed on non-immunologic outcomes that contribute to patient morbidity and mortality. [1] [2] The onset of post-transplant diabetes mellitus (PTDM) has been linked to higher rates of cardiovascular disease and infection, and it is a major cause of morbidity and mortality. 1 Risk factors for PTDM in kidney transplant recipients are similar to those in the non-transplant population 2 . The consequences of diabetes are also the same, such as increased risk of cardiovascular disease, infection, nephropathy, neuropathy, and retinopathy. [1] [2] [3] International consensus guidelines regarding the definition of new-onset diabetes mellitus (DM) after transplantation used standard World Health Organization (WHO) and American Diabetic Association (ADA) criteria for diagnosis of DM as well as impaired glucose tolerance. [1] [2] Importantly, the use of glycated hemoglobin (HbA1c) is not recommended before three months post-transplant, as the test may not be valid until new hemoglobin has been synthesized and glycated for the appropriate period in the diabetogenic Background and objective: The onset of post-transplant diabetes mellitus has been linked to higher rates of cardiovascular disease and infection. The aim of this study was to evaluate the incidence of post renal transplant diabetes. More specifically, they study tried to find out the demography of patients with post transplant diabetes mellitus, their anthropometric measures, the incidence rate in different periods and among different demographic variables. Methods: Seventy patients transplanted in different centers in Iraq were enrolled in the study. The patients were followed up for more than one year during their visits and or admission to the Dialysis Unit 
Inclusion criteria:
All patients with kidney transplant were recorded in this study.
Exclusion criteria:
Twelve patients were excluded in the study because they had DM. The remaining seventy patients were enrolled in the study.
Laboratory examinations:
A complete history and physical examination and previous blood tests with new blood tests were performed and reported. Oral glucose tolerance tests were not performed to our patients. Fasting and random blood sugars were reviewed, and new blood sugar tests were performed. 1 The results of the HLA matching were questioned for every patient and reported. For related donors, the HLA matching and the degree of compatibility were reported as haplotype matching. For unrelated donors, only white cell cross match was done. Diagnostic criteria: Post transplant diabetes mellitus (PTDM) was diagnosed according to the WHO and ADA criteria for the diagnosis of DM, 5 such as symptoms of diabetes plus casual PG concentration ≥200 mg/dl (11.1mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss, or FPG ≥126 mg/dl (7mmol/l). Fasting is defined as no caloric intake for at least 8 hours, or 2 hours PG ≥200 mg/dl (11.1mmol/l) during an oral glucose tolerance testing using a glucose load among different demographic variables. post-transplant setting. 2 Because of varied definitions, the incidence of PTDM is difficult to determine. It has also changed over the past decades with changes in definition, immunosuppression regimens, and patient demographics. The incidence of PTDM was systematically reviewed by many studies, 1,4-7 12 months cumulative incidence estimation of PTDM were reported to be within the range of 2-53%. In 1979, rates as high as 46% were reported; this rate was attributed in part to the use of high doses of steroids, occurring as long as 20 months post-transplant. 4 Subsequent estimates are that the development of DM occurs among approximately 9%, 16%, and 24% at 3, 12, and 36 months post-renal transplantation, respectively. [5] [6] [7] Many of the same risk factors that predispose non-transplant patients to DM have been identified as risk factors for its development after transplantation. In addition, unique factors, such as immunosuppression, HLA mismatch, donor gender, and the underlying renal disease, may also enhance the risk of PTDM. 8 The factors including increased age, [4] [5] 9 obesity, [9] [10] [11] [12] race and ethnicity, 5-6,13-16 family history, 16 HLA matching and donor characteristics, 1, 5 infection such as Hepatitis C Virus (HCV) 5, [17] [18] [19] [20] and Cytomegalovirus, [21] [22] type of underlying renal disease [23] [24] and medications such as glucocorticoids, [25] [26] [27] [28] Calcineurin inhibitors, 3 , 5 , 7 , 1 8 , 1 4 , 2 9 -3 3
Sirolimus [34] [35] and immunosuppressive combination regimens such as combination of tacrolimus and azathioprine. 32, 36 The risk of PTDM in Iraq is unknown. Studying PTDM, their associated risk factors and choices of immunosuppressive therapy will help the physician to have a better understanding of the incidence of PTDM and manage their associated risk factors as well as paying careful attention to the choice of the immunosuppressive regime to decrease the risks of PTDM. The objectives of this study were to find out the demography of patients with PTDM, their anthropometric measures, the incidence rate of PTDM in different periods and containing an equivalent of 75 g anhydrous glucose dissolved in water. Normal fasting plasma glucose (FPG) < 110 mg/dl (6.1mmol/l). Impaired fasting glucose (IFG) ≥ 110 mg/dl (6.1mmol/l) and < 126 mg/dl (7 mmol/l). Normal glucose tolerance: 2-hour PG < 140 mg/dl) 7.8 mmol/l). Impaired glucose tolerance: 2-hour PG ≥ 140 mg/dl (7.8 mmol/l) and < 200 mg/dl (11.1 mmol/l). The body mass index (BMI) was calculated for our patients from the equation below: BMI = weight (kg)/height (m 2 ). Hypertension, defined as systolic blood pressure more or equals 140 mm/Hg and or diastolic blood pressure more or equals 90 mm/Hg, or patient's blood pressure controlled with antihypertensive medication. 37 All patients included in this study received steroid in the form of prednisolone tablets (5-10 mg) daily after transplant, only five patients of them received steroid also before transplant between 1-3 years (patients their renal failure due to nephrotic syndrome In this study, the incidence of DM in the first three months post transplantation was (14%); interestingly, no one of those patients developed permanent DM that required treatment. High dose steroids (IV or oral) used for induction or for treating acute rejection episodes and high doses of cyclosporine initially used for induction, both might contribute to the hyperglycemia initially observed in those patients. [4] [5] [6] [7] 9 Many studies associated the use of high dose of immunosuppression with early hyperglycemia and was not mentioned as a risk factor for developing permanent DM later. 1, [4] [5] [6] [7] In this study, the exact dose of steroid used initially was not reported, and the rejection episodes were not entailed. This group of PTDM was treated transiently for few days with subcutaneous insulin, and no one of those patients needed long term therapy. No association between steroid use and DM in this study was observed. In the current study, increased age was statistically associated with the development of PTDM (P <0.018), permanent DM requiring treatment was found in (17%). Although other studies have reported higher incidence than the current study such as a study conducted in 2004 38 reported the incidence of hyperglycemia in the first month post transplantation to be (38.7%) and after that up to 6 months to be (22.6%) but the number of patients in such study was small and the follow up period was short. There are other studies recorded similar low incidences as our study. Kasiske et al. in 2003 reviewed the incidence and risk factor for developing PTDM in 11659 patients; they found that the incidence of PTDM was (19%) and increasing age and hepatitis C virus was associated with the development of PTDM. 5 Roth et al. in 1989 reported an incidence of (18.6%) of PTDM in 908 patients followed up for ten years. Increased age greater than forty years associated with higher incidence of PTDM. High BMI was also significant risk factor. 39 In the current study, high serum triglyceride level was significantly associated with the development of PTDM. The mean triglyceride level of more than 161 mg/dl in our study was associated with the development of PTDM. Cosio et al. in 2002 included 1811 patients transplanted in a single institution between 1983 and 1998 also found hypertriglyceride of more than 200 mg/dl was particularly pronounced in PTDM and elevated triglyceride levels correlated with the development of PTDM independent of other risk factors. Increasing BMI and African American was also associated with increase the risk of development of PTDM. 10 Vesco et al. in 1996 reviewed the incidence and risk factors of PTDM in 1325 patients and found that a high BMI and increasing age is also associated with the development of PTDM. Triglyceride level more than 200 mg/dl was associated with the development of PTDM. 40 Although many studies proved an association between high BMI and the development of PTDM, 1,4-7 in our study there was no difference in the mean BMI in diabetics and nondiabetics and when compared with other studies. The mean BMI was higher than that reported among our patients. This difference is probably related to the nutritional status of the patients and adequacy of dialysis before transplantation. Generally speaking, the adequacy of dialysis in our country is suboptimal, and malnutrition with weight loss is a usual feature of our patients. Small sample size may also have affected the results. Family history was positive in 27% of patients with PTDM versus 18% nondiabetics, but it does not reach statistically significant association. In many studies, the association of hepatitis C virus infection with PTDM was reported. A meta-analysis in 2005 of ten studies including 2,502 patients found that anti-HCV positive patients were nearly four times more likely to have PTDM compared with uninfected individuals. 21 In addition, at least one group has shown decreased incidence of new-onset diabetes with the Discussion treatment of hepatitis C infection before transplantation. 41 In our study, there was no statistically significant association between hepatitis C virus infection and PTDM. This might be attributed to the small number of patients infected with hepatitis C virus in this study, in addition in our country, we almost exclude patients infected with hepatitis C virus from the waiting list for the transplant. Polycystic kidney disease may confer an increased risk of PTDM, although this has not been consistently observed. [24] [25] 42 In our study, there was only one patient with polycystic kidney disease transplanted and he developed PTDM. Pulsed high-dose therapy for acute rejection also appears to be a particularly strong risk factor for PTDM. 40 The use of pulse steroid therapy of our patients was not recorded and all of them were on the same dose of steroid therapy (10 mg/day). There was no attempt to stop steroid or to lower the dose to calculate the difference. A review of 11,659 USRDS patients reported that initiation with tacrolimus as maintenance therapy was associated with a 1.53 relative risk of PTDM over that observed with nontacrolimus containing regimens. 5 Another study found that the incidence of PTDM by two years after transplantation was increased approximately 70% in renal transplant patients on tacrolimus versus cyclosporine-based regimens. 7 In our study, cyclosporine use was not associated with the development of PTDM; all patients were receiving the drug without level monitoring. No patient in our study received tacrolimus. Mycophenolatemofetil (MMF) was used in 70%, Azathioprine was used in 30% of the patients included in this study, and there was no statistically significant association with the development of PTDM. Azathioprine, mycophenolatemofetil (MMF) do not have independent diabetogenic effects. 5 The use of azathioprine and MMF in our study was actually associated with a decreased risk of PTDM (16% and 22%, respectively). This benefit may be due to the ability to permit the use of lower doses of corticosteroids, although this is unproven.
Conclusion
The incidence of PTDM is high compared to other studies. Post transplant DM is an important complication that the transplant physicians should screen for in every transplanted patient. Increasing age and serum triglyceride levels may be regarded as predictors for the development of PTDM. The choice and the doses of immunosuppressive therapy is another modifiable risk factor for PTDM, and careful attention should be giving to the choice of immunosuppressive
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